A study presented at the 2019 ASCO Annual Meeting and conducted in institutions participating in the International Neoadjuvant Melanoma Consortium pooled data from six neoadjuvant systemic therapy trials (anti-PD-1 in 133 patients and BRAF/MEK target therapy in 55 patients). This evidence concerns the gene BRAF and melanoma.